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WE estimated the serum levels of IL-6, TNF-a and IL-
10, and generation of superoxide radicals, as well as
their  mutual  dependence,  in  63  SLE  patients  at
various stages of disease activity. Our results indicate
a statistically significant increase of the serum levels
studied, and an increase of superoxide anion genera-
tion by granulocytes, in correlation with SLE activity.
These results indicate  that  oxygen metabolism  and
the  examined  cytokines  play  an  important  role  in
pathogenesis of SLE. The assessment of these para-
meters  can  be  useful  in  the  estimation  of  disease
activity.
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Introduction
Systemic lupus erythematosus (SLE) is a multisystem
disease that is caused by tissue damage resulting from
antibody  and  complement-fixing  immune  complex
deposition. Inflammatory responses triggered by local
formation  and  deposition  of  antigen–antibody
immune  complexes  are  responsible  for  the  clinical
manifestations of vasculitis and involvement of inter-
nal organs. Inflammation in systemic lupus erythema-
tosus,  mediated  by  a  complex  interaction  of  the
cellular  and  humoral  components  of  the  immune
response, plays an important role. For years SLE has
been  considered  as  a  disease  caused  by  B  cell
hyperactivity and concomitant T cell hyperactivity.1
However, currently many authors claim that SLE is a T
cell-dependent disease.2
In order to explain the mechanisms responsible for
immune regulation in SLE, cytokines have become the
object  of  intensive  studies.3,4 These  proteins  may
affect different cells and are also involved in immunity
processes  and  inflammatory  responses.  Some  data
show  that  interleukin-6  (IL-6)  and  tumor  necrosis
factor-a (TNF-a )  play  an  important  role  in  the
pathogenesis of SLE.5
According to  some  studies,  interleukin-10  (IL-10)
plays  a  superior  role  over  IL-6  and TNF-a in  some
autoimmunological  and  inflammatory  diseases,
including SLE.6–8 Interleukin-10 is a pleiotropic cyto-
kine  produced  mainly  by  lymphocytes  T  and  B,
monocytes and mastocytes. It exerts multidirectional
influence  on  the  processes  of  immunological
response  and  inhibits  the  production  of  IFN-g by
lymphocytes T,  and  IL-6,  IL-1  and TNF-a by  macro-
phages. It also suppresses the production of  active
oxygen  forms  by  activated macrophages, and  stim-
ulates the proliferation and differentiation of lympho-
cytes  B  and  the  synthesis  of  immunoglobulins  by
these cells, in particular in the presence of IL-4. The
literature on the role of IL-10 in the development of
SLE is scarce and controversial.6
In recent years active oxygen forms produced in
the processes of biological oxygenation and reduction
have raised the interest of researchers.9 Spontaneous
non-controlled  reactions  which  give  excessive
amounts of active oxygen forms, and cause defects of
protective enzymes, may  be  one of  the pathogenic
elements in the diseases of inflammatory background,
like  SLE.10,11 The  most  common  reactive  oxygen
forms in the human organism are: superoxide anion
radical (O2
.–), hydroxyl radical (OH.), hydrogen per-
oxide (H2O2), nitrogen oxide (NO) and others.
The mechanism of destruction of cells and tissues
caused by superoxide radicals is based on both direct
toxic influence  on  the cells  and indirect effect via
the  production  of  other  biologically  active
compounds.12
The goal of our study was to estimate the serum
levels  of  IL-6,  TNF-a ,  IL-10  and  superoxide  anion
radicals in patients suffering from SLE. In this study
we tried to find the correlation between the serum
levels of these parameters and the disease activity.
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The study comprised 63 patients with SLE (60 women
and three men) aged between 12 and 60 years. The
diagnosis was based on the presence of at least four
out  of  11  diagnostic  criteria  established  by  the
American Rheumatological Association. The duration
of the disease was from 4 months to 24 years. During
our study 51 patients were treated with glycocortico-
steroids, and five with glycocorticosteroids in combi-
nation with azathioprine (Table 1). In all patients the
activity of the disease was determined according to
the SLAM (systemic lupus activity measure) scale, as
described  by  Liang  et  al.13 It  lists  33  clinical  and
laboratory  manifestations  of  SLE.  Each  of  them  is
assessed as either active or inactive. Possible scores
with this scale vary from 0 to 86 points.
The active stage of the disease (over 10 points) was
found in 32 patients, including  21 not treated with
immunosuppression. The remaining were in clinical
remission, among whom seven were not treated and
24  were  treated  with  low,  maintenance  doses  of
immunosuppressive  drugs  (Table  2).  The  control
group constituted 16 normal individuals, matched for
sex and age.
Laboratory tests
On the day of blood sampling for IL-6, TNF-a , IL-10
and  the  following  laboratory parameters were  ana-
lysed: complete blood cell count (CBC), erythrocyte
sedimentation  rate  (ESR),  blood  urea  nitrogen  and
creatinine level, fibrinogen level, partial thromboplas-
tin time (PTT), immunoglobulins (IgG, IgA, IgM) and
complement (C3, C4), urine level and the level of anti-
DNA antibodies.
Serum sampling
Venous  blood  samples  for  cytokines  determin-
ations  were  collected  into  pyrogen-free  tubes  and
centrifuged within 20min after being allowed to clot
at –4°C for 1h at 2000g for  10min at the time of
clinical  assessment. The serum  obtained by  us  was
divided  into  aliquots  and  stored  at  –25°C  until
assayed. IL-6, TNF-a , IL-10 were assayed by specific
commercially available, enzyme-linked (ELISA) assay
kits (Quantikine, R&D Systems Inc., USA) in accord-
ance with the manufacturer’s protocols.
In each assay the appropriate recombinant human
cytokine was used to generate the standard curve. The
sensitivities of the assay were: IL-6, 0.3pg/ml; TNF-a ,
0.5pg/ml;  IL-10,  7.8pg/ml.  The  generation  of  the
superoxide anion radical by peripheral blood granulo-
cytes was determined by the method of Bellavite et
E. Waszczykowska et al.
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Table 1. Clinical data
Studied group
Sex
Group I
F M
Group II
F M
Group III
F M
Group IV
F M
Control group
F M
Number of
patients
20 1 11 0 21 3 7 0 15 1
Age (years) 20–60 16 24–59 – 26–61 38–60 31–55 – 16–60 45
Duration of
the disease
3 months
– 5 years
5 months 3 months
– 3 years
– 1–10
years
2–8
years
4–15
years
– – –
Treatment
(mg per day)
Not
treated
Not
treated
P 40–60
or
D 8–12
P 40–60
or
D 8–12
P 10–20
and/or
A 50–100
P 10–20
and/or
A 50–100
Not
treated
– Not
treated
Not
treated
SLAM scale >10 >10 >10 >10 <10 <10 <6 – – –
D, dexamethasone; P, prednisone; A, azathioprine
Table 2. Clinical characteristics of 63 patients with SLE
Symptom Number
of patients
%
Total 63 100
Active 32 50.8
Inactive 31 49.2
Malaise, fever 30 47.6
Cutaneous and mucous membrane
lesions
55 87.3
Lymphadenopathy, splenomegaly,
hepatomegaly
29 43.0
Pneumonitis and/or pleurisy 8 12.7
Cardiovascular disorders and
Raynaud’s phenomenon
49 77.8
Gastrointestinal disorders 9 14.3
Central and/or peripheral nervous
system involvement
43 68.3
Arthralgia and/or arthritis 46 73.0
Abnormal blood count, elevated ESR 51 81.0
Abnormal urinalysis, raised serum
creatinine level
25 39.7
ANA>160, ds DNA, Sm 58 92.1al.,14 based on evaluation of the degree of reduction
of cytochrome C by superoxide radicals generated by
periferal blood granulocytes. Supernatant absorbtion
was determined on a Specol 11 spectrophotometer.
Statistical analysis
Differences  in  parameters  between  groups  were
evaluated with Student’s t-test. The chi-squared and
Fisher’s exact tests were used to analyse the relation-
ship between cytokines and generation of O2
.– at rest
and  in  periods of  SLE  activity.  Internal  distribution
data were  analysed  by  Student’s  t-test.  Correlations
were evaluated using Spearman’s rank-serum correla-
tion coefficient and linear regression calculated with
the least-squares method. Results are presented with
R2 coefficients. Comparisons and correlations were
considered significant when P<0.05.
Results
The  concentration  of  IL-6,  TNF-a ,  IL-10  and  the
generation  of  anion  radical  O2
.– was  significantly
higher in patients with SLE and correlated with the
activity  of  the  disease  (Fig.  1). Table  3  shows  the
results of measurement of IL-6, TNF-a , IL-10 and O2
.–
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FIG. 1. Correlations between serum level of IL-10, IL-6, TNF-a and generation of O2
.– with SLE activity.in the serum of all patients with SLE, treated and not
treated, and 16 normal individuals. In patients with
SLE,  mean  level  of  IL-6  was  5.63pg/ml  and  was
statistically  significantly  higher  in  comparison with
the  control  group  (P<0.001).  The  highest  level  of
this cytokine was observed in patients who were at
the most active phase of the disease (>10 points in
SLAM scale). In our own studies the mean level of
TNF-a in patients with SLE was 3.2pg/ml, while in
the  control group  of  normal  subjects  it  was  many
times  smaller,  0.65pg/ml.  The  difference  in  the
concentration  of  this  cytokine  in  all  the  patients
with SLE and in group 1 was statistically significant
(P<0.001) and its level correlated with the activity of
the  disease. The  highest  level  of  this cytokine was
observed  at  the  most  active  phase  of  the  disease,
before treatment had started. After 7 days of therapy
the mean level of TNF-a in these patients decreased
significantly  and  was  similar  to  that  observed  in
patients in the non-active phase (<10 points in SLAM
scale).
Mean concentration of IL-10 in the studied patients
was 8.6pg/ml and it was three times higher than in
the control group. The level of IL-10 concentration,
E. Waszczykowska et al.
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Table 3. Serum levels of IL-6, TNF-a , IL-10 and generation of O2
.– in patients with SLE and control group
Parameter Patients
number
Group I
(active
phase
not treated)
Group II
(active
phase
treated)
Group III
(clinical
remission)
Group IV
(clinical
remission
not treated)
Control
group
Statistical
analysis
for average
n=63 n=21 n=11 n=24 n=7 n=16
(a) (b) (c) (d) (e) (f)
IL-6 a&f P<0.009*
b&f P<0.001*
c&f P<0.04*
d&f P>0.05
Min–max 0.1–63.3 1.2–63.3 0.2–36.2 0.1–14.8 0.4–1.95 0.3–4.8 e&f P>0.05
Me 2.1 2.9 2.5 1.15 1.1 1.0 b&c P>0.05
Mean ± SD 5.63±11.41 10.75±17.11 5.56±10.27 2.50±3.15 1.14±0.52 1.31±1.17 b&d P<0.002*
b&e P<0.001*
c&d P>0.05
c&e p=0.052
d&e P>0.05
TNF-a a&f P<0.001*
b&f P<0.001*
c&f P<0.001*
d&f P<0.001*
Min–max 0.4–9.8 0.6–9.8 1.2–5.3 0.4–6.8 0.5–3.8 0.1–1.6 e&f P<0.03*
Me 3.1 4.1 3.2 2.3 1.4 0.5 b&c P<0.03*
Mean ± SD 3.20±2.01 4.40±2.11 2.99±1.14 2.75±1.93 1.51±1.14 0.65±0.41 b&d P<0.01*
b&e P<0.003*
c&d P>0.05
c&e P<0.05*
d&e P>0.05
IL-10 a&f P<0.001*
b&f P<0.001*
c&f P<0.001*
d&f P<0.001*
Min–max 2.0–25.4 5.5–25.4 5.7–20.9 2.0–13.0 2.0–9.0 0.0–5.9 e&f P>0.05
Me 6.9 11.1 8.1 5.4 3.2 2.0 b&c P>0.05
Mean ± SD 8.61±5.28 12.04±5.64 10.72±5.27 5.97±2.72 4.00±2.35 2.50±2.07 b&d P<0.001*
b&e P<0.001*
c&d P<0.004*
c&e P<0.004*
d&e P<0.05*
Generation a&f P<0.001*
of O2
.– b&f P<0.001*
c&f P<0.001*
d&f P<0.001*
Min–max 9.16–35.00 14.78–32.16 9.64–20.18 10.31–35.00 9.16–12.63 5.13–11.34 e&f P<0.009*
Me 14.85 18.75 14.28 13.57 10.57 8.82 b&c P<0.002*
Mean ± SD 16.35±5.69 20.95±5.49 14.58±3.55 14.81±4.67 10.57±1.15 8.51±1.73 b&d P<0.001*
b&e P<0.001*
c&d P>0.05
c&e P<0.009*
d&e P<0.005*
*Differences statistically significant.similar to that of IL-6 and TNF-a , correlated with the
activity  of  the  disease  (Fig.  1).  Similar  to  other
authors,15 we have not found dependence between
the  concentration of  this cytokine and the  applied
treatment in our group of patients. However, the level
of this cytokine was found to correlate with the levels
of TNF-a , IL-6 (Fig.  2)  and the generation of supra-
oxide anion radical (Fig. 3c). The degree of generation
of  O2
.– was significantly  higher in the patients and
positively correlated with the activity of the disease
and applied immunosuppressive treatment (Table 3).
Also, a statistically significant positive correlation was
seen between the concentration of all studied cyto-
kines and the level of O2
.– generation (Fig. 3). We have
not observed any influence of the applied treatment
on IL-6 and IL-10, either in the active or non-active
phases. However, the treatment in the active phase
statistically significantly decreased the level of TNF-a
concentration and degree of O2
.– generation (Table
3).
Discussion
The pathogenesis of systemic lupus erythematosus is
still not fully  understood. Recent studies show that
some  cytokines  play  a  role  in  the  immunological
dysregulation in this disease: the literature indicates
cytokines  of  the  inflammatory  group,  i.e.  IL-6  and
TNF-a .16,17 Elevated levels of IL-6 have been repor-
ted  in  neoplasms,  infections  and  immunological
diseases.18 After treatment, the concentration of this
cytokine  decreased almost  two-fold,  which  can  be
explained by the significant influence of glycocorti-
costeroids  on  the  synthesis  of  this  cytokine.  In
clinical  remission,  patients  receiving  maintenance
doses  of  drugs  showed  a  further  decrease  in  the
level  of  this  cytokine. The  results  obtained  in  this
group  were  statistically  significantly  lower  than
those  from  patients  in  a  more  active  phase.  In
clinical  remission  of  activity  (score  <10  points  in
SLAM scale) the levels  of IL-6 were the lowest and
did  not  differ  statistically  from  those  in  normal
subjects.  No  statistically  significant  difference  was
noted  as  to  the  mean  concentrations  of  IL-6  in
treated and non-treated patients in the active phase.
This fact may be due to the increased expression of
cellular  receptors  for  this  cytokine  during  treat-
ment.19 Increased levels of IL-6 in various diseases of
the  connective  tissue  were  described  by  other
authors.16,17,20,21 Spronk  et  al.,22 in  a  group  of  71
patients with systemic lupus erythematosus, demon-
strated statistically significantly  higher levels  of this
cytokine in those patients who were in the exacer-
bated phase, and in particular in those cases where
changes in the central nervous system were present.
Also, in vitro studies confirm the role of IL-6 in the
development of  SLE,  as  they  showed  that  lympho-
cytes T and  B  and monocytes of patients with SLE
produce higher amounts of this cytokine compared
to normal subjects.16
TNF-a has  a  peculiar  effect  on  human  SLE  B
cells.  This  cytokine  is  a  growth  factor  in  normal
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FIG. 2. Correlations between IL-10 and TNF-a and between IL-10 and IL-6 serum concentrations in patients with SLE.individuals, but in patients with SLE it inhibits B cell
proliferation and spontaneous production of  IgM.23
Several groups  have reported that in vitro produc-
tion  of  TNF-a by  stimulated  PBMCs  decreases  in
human  SLE.24 At the same time, other investigators
have reported that serum levels of TNF-a in SLE are
normal or increased.17,25–27 The mechanism of TNF-
a action in SLE is unclear. Although TNF-a protects
NZB/NZW mice from the renal disease, this therapy
does not decrease the titers of anti-DNA antibodies.
Moreover,  treatment  with  low-dose  TNF-a accel-
erates renal disease and mortality rate. This phenom-
enon  is  probably  connected  with  an  immunosup-
pressive  influence  of  glycocorticosteroids  on
biosynthesis of TNF-a .28 Only  one report27 did not
show  a  correlation  between  the  concentration  of
this  cytokine  and  the  activity  of  the  disease. This
may be due to different sensitivity and specificity of
the  determination  method  used,  e.g.  immunoenzy-
matic or biological method, and the numbers in the
groups  studied.
Interleukin 10 is a pleiotropic cytokine which may
exert  immunostimulating  and  immunosuppressive
effects on various types of cells.7 IL-10 is a cytokine
with  an  suppressive  effect  on  antigen  presentation
and T  cell-mediated  immune  reactions,  and  is  also
capable of stimulating polyclonal IgG synthesis.29
In  vitro studies  revealed  that  IL-10  plays  a  sig-
nificant role in the pathogenesis of SLE. Administra-
tion  of  anti-IL-10  antibodies  delayed  autoimmunisa-
tion processes and the formation of renal changes in
an animal model on New Zealand mice, NZB/NZW
F1.8 Also,  in  vitro studies  showed  that  stimulated
mononuclears from peripheral blood of patients with
SLE  produce  increased amounts  of  this  cytokine.30
Both  in  vivo and  in  vitro studies  revealed  that
antibodies against IL-10 decrease the production of
immunoglobulins, including anti-DNA antibodies.29 It
is extremely interesting that the dysregulation of IL-10
production, previously identified in  SLE  patients, is
also  present  in  healthy  members  of  families  with
several  cases of  SLE,  and  it  may  contribute  to  the
immunological abnormalities affecting the relatives of
SLE patients.31
These  observations  may  confirm  not  only  the
importance of this cytokine in the pathogenesis and
course of SLE, but also its superior role over other
studied  proteins  which  take  part  in  the  cytokine
cascade. Literature  on  the  possibility  of  determina-
tion of IL-10  in  serum  of patients with  SLE  and in
healthy individuals is controversial. Houssiau et al.15
found detectable concentrations of this cytokine in
only 37% of sick and 3% of healthy subjects. In our
own studies, detectable levels of  this protein were
found both in the studied group and in the control
group. In SLE patients it was also found to correlate
with  the  activity  of  the  disease.  It  seems  that  the
increased  release  of  this  cytokine  in  patients  with
SLE  is  connected  with  a  defect  of  its  inhibitory
effect on other cytokines.
In  inflammatory  diseases,  including  SLE,  phago-
cyte  cells  surrounding  immunological  complexes
release  high  amounts  of  highly  reactive  oxygen
forms, including supraoxide anion radicals, into the
E. Waszczykowska et al.
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FIG. 3. Correlations between generation of O2
.– and TNF-a , IL-6, IL-10 serum concentrations in patients with SLE.extracellular  space,32 which  in  turn  affect  cellular
structures,  damaging  them,  or  in  favourable  condi-
tions reacting with iron ions. The direct effect of this
oxygen  outbreak is damage to cellular  membranes.
The  literature  on  the  level  of  active  oxygen  form
production,  and  their  role  in  the  pathogenesis  of
inflammatory diseases is controversial. Ara and Ali,33
in their group of SLE patients, found higher produc-
tion of free radicals and lipid superoxides compared
to  normal  controls. The  authors  claim  that  these
radicals  may  enhance  the  production  of  autoanti-
bodies,  inflammatory  changes  in  the  kidneys  and
other internal organs. Witt et al.34 claim that deter-
mination  of  the  level  of  free  radical  generation,
dependent upon local release of cytokines, may be
useful in the evaluation of the severity of pulmonary
changes in  SLE and systemic sclerosis patients.
Benke et al.35 report lack of correlation between
the degree of O2
.– generation and the activity of the
disease,  although  they  found  increased  production
in free radicals in patients with SLE. Our own results
indicated  that  while  the  activity  of  the  disease
increases, a significant growth in superoxide radicals
generation is observed P<0.001. Positive correlation
between  the  level  of  release  of  free  radicals  and
levels  of  studied  cytokines  indicates  that  oxygen
metabolism plays an important role in the pathogen-
esis of SLE.
Under  physiological  conditions  IL-10  inhibits
both7,31 the  process of  IL-6, TNF-a release and the
generation  of  O2
.–.  In  the  group  of  the  patients
examined  by  us  we  did  not  observe this  phenom-
enon. Despite this, there was a statistically significant
positive  dependence between the  concentration of
IL-10 and levels of IL-6 and TNF-a and generation of
O2
.–. This pathological reaction is probably caused by
a defect of inhibiting influence of IL-10 in SLE patients
on other parameters examined by us.
Oxidative stress functions like a triggering mecha-
nism,  leading  to  an  increased  production  of  a
number  of  cytokines,  including  IL-6  and  TNF-a .
Lymphokines  stimulate  polynuclear  lymphocytes  to
phagocytosis  and  degranulation,  and  thus  increase
the  generation  of  free  oxygen  radicals.  Oxidative
stress and processes responsible for the production
of  cytokines  interact  reciprocally  like  a  vicious
circle, and therefore it is difficult to state the reason
for  this  and  what  the  result  is.  Possibly  all  these
mechanisms  together  play  a  significant  role  in  the
pathogenesis  and  course  of  SLE.  Our  own  results,
and the demonstrated correlation between the ana-
lysed  proteins and the  activity of the  disease, con-
firm  this  hypothesis.  As  IL-10  seems  to  play  a
superior role over the cascade of reaction of release
of  cytokines and active oxygen  forms,  which leads
to cell destruction, monitoring the concentration of
this cytokine may be useful in the evaluation of the
activity of  the disease.
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